ATR was discussed at WCLC 2026 as a therapeutic target in the DNA damage response…
Browsing: biotech analysis
Jiangsu Hengrui Pharmaceuticals was present at WCLC 2026 abstracts through its extensive oncology portfolio, including…
MET was featured at WCLC 2026 highlights, with MET exon 14 skipping alterations, MET amplification,…
Pfizer was present at WCLC 2026 abstracts through its oncology portfolio, including lorlatinib and other…
Gilead Sciences was present at WCLC 2026 abstracts through its oncology portfolio and research collaborations…
DLL3 was a transformative target at WCLC 2026 late-breaking abstracts, with tarlatamab and the DeLLphi-308/309…
The PROACC-1 trial was featured at WCLC 2026 oral presentations in oral presentations, examining a…
EGFR remained the most extensively targeted oncogenic driver at WCLC 2026 oral presentations, with osimertinib,…
The LIBRETTO-432 trial was a highlight at WCLC 2026, presented in WCLC 2026 oral presentations.…
Cancer cachexia in lung cancer was discussed at IASLC WCLC 2026 in sessions focused on…